Literature DB >> 7954023

5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation.

Z Sasson1, C D Morgan, B Wang, G Thomas, B MacKenzie, M E Platts.   

Abstract

This report describes two cases of cardiotoxicity associated with the use of 5-fluorouracil (5-FU) in the treatment of neoplastic disease, and reviews the literature to date. The manifestations of cardiac toxicity were significant ventricular dysfunction during continuous infusion of 5-FU, accompanied by symptoms resembling cardiac ischemia in one case and irreversible cardiogenic shock in another. Detailed cardiac investigations and pathological findings provide convincing evidence that the development of acute myocarditis is the likely mechanism of 5-FU cardiotoxicity, rather than coronary insufficiency as has commonly been postulated. Although cardiotoxicity as a complication of 5-FU therapy remains rare, recognition of this entity is important as it may lead to serious hemodynamic compromise and may recur with drug rechallenge.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954023

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  12 in total

1.  Thrombophilia, left ventricular dysfunction and intracardiac thrombi in children.

Authors:  Ibrahim Abu-Kishk; Shaul Baram; Eran Kozer; Baruch Klin; Gideon Eshel
Journal:  Korean Circ J       Date:  2011-08-31       Impact factor: 3.243

Review 2.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

3.  Reversible cardiogenic shock following 5-fluorouracil infusion.

Authors:  Charles Ferté; Carlos Gomez Roca; Yohann Loriot; Rastislav Bahleda; Cristian Moldovan; Ariel Cohen; Hassan Izzedine; Jean-Charles Soria; Stephane Ederhy
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

4.  Rapid Extracorporeal Membrane Oxygenation Overcomes Fulminant Myocarditis Induced by 5‑Fluorouracil.

Authors:  Alok R Amraotkar; Ajay Pachika; Kendra J Grubb; Andrew P DeFilippis
Journal:  Tex Heart Inst J       Date:  2016-04-01

5.  5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI.

Authors:  Yama Fakhri; Morten Dalsgaard; Dorte Nielsen; Per Lav Madsen
Journal:  BMJ Case Rep       Date:  2016-06-01

6.  Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity.

Authors:  Michael G Fradley; Conor D Barrett; John R Clark; Sanjeev A Francis
Journal:  Tex Heart Inst J       Date:  2013

7.  Is there a role for remote ischemic conditioning in preventing 5-fluorouracil-induced coronary vasospasm?

Authors:  Jun Chong; Andrew Fw Ho; Jonathan Yap; Heerajnarain Bulluck; Derek J Hausenloy
Journal:  Cond Med       Date:  2019-10

Review 8.  A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity.

Authors:  Anne Polk; Kirsten Vistisen; Merete Vaage-Nilsen; Dorte L Nielsen
Journal:  BMC Pharmacol Toxicol       Date:  2014-09-04       Impact factor: 2.483

9.  What the Cardiologist Needs to Consider in the Management of Oncologic Patients with STEMI-Like Syndrome: A Case Report and Literature Review.

Authors:  Aneta Aleksova; Giulia Gagno; Alessandro Pierri; Carla Todaro; Alessandra Lucia Fluca; Valentina Orlando; Alessandra Guglielmi; Antonio Paolo Beltrami; Gianfranco Sinagra
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-12

10.  Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.

Authors:  Christos Kosmas; Manolis S Kallistratos; Petros Kopterides; John Syrios; Helias Skopelitis; Nicolaos Mylonakis; Athanasios Karabelis; Nicolas Tsavaris
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-17       Impact factor: 4.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.